T1	Participants 83 123	in advanced epithelial ovarian carcinoma
T2	Participants 182 385	patients randomised in a previously reported multicentre phase III study of topotecan versus paclitaxel in patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen
T3	Participants 408 456	Patients with bidimensionally measurable disease
T4	Participants 957 969	226 patients
T5	Participants 1831 1839	patients
